Investor Relations

Press Releases

 
Press Releases
  Date Title and Summary View
Jun 13, 2016
NEWARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today reported results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel (RT001) to treat patients with moderate to severe later...
Jun 2, 2016
- Portfolio covers diverse and novel indications, compositions and formulations - - Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders- NEWARK, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in ...
May 31, 2016
NEWARK, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance management is scheduled to present at the Jeff...
May 9, 2016
- Completes Enrollment in REALISE 1 Phase 3 Trial for RT001 Topical for Crow's Feet Lines -- Moves Phase 2 Dose-Escalating Trial for RT002 Injectable for Cervical Dystonia into Second Cohort - NEWARK, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin product...
Apr 25, 2016
NEWARK, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the Company will release first quarter 2016 financial results on Monday, May 9, 2016 after the close of market. Revance will...
Apr 4, 2016
NEWARK, Calif., April 4, 2016 - Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, proudly announces that its Chief Operating Officer Abhay Joshi, Ph.D., MBA, was inducted today to the American Institute of Medical and Biological Engineeri...
Mar 14, 2016
NEWARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced a key addition to its leadership team with the appointment of Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Devel...
Mar 5, 2016
- Findings confirm statistically significantly greater duration of effect for RT002 compared to BOTOX® Cosmetic - - 40U dose of RT002 planned to enter pivotal Phase 3 study in the second half of 2016 - NEWARK, Calif., March 05, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinu...
Mar 2, 2016
- Announces 2016 Outlook -- On Track to Achieve Multiple Clinical Development Milestones in 2016 - NEWARK, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today results for the fourth q...
Feb 23, 2016
NEWARK, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today that the Company will be participating in two upcoming investor conferences. Revance management is scheduled to...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Shareholder Tools